INOVIO PHARMACEUTICALS, INC. — Director's Dealing 2021

Apr 21, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: INOVIO PHARMACEUTICALS, INC. (INO)
CIK: 0001055726
Period of Report: 2021-04-21

Reporting Person: Weiner David B. (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-04-21	Common Stock	M	22500	$2.40	Acquired	877719	Direct
2021-04-21	Common Stock	S	22500	$8.57	Disposed	855219	Direct
2021-04-21	Common Stock	S	4083	$8.54	Disposed	851136	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-04-21	Common Stock Options	$2.4	M	22500	Disposed	2022-02-23	Common Stock (22500.0)	Direct

Footnotes

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F2: These transactions were executed in multiple trades at prices ranging from $8.49 to $8.66, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

F3: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Reporting person intends to use the proceeds of this sale to pay taxes resulting from the recent vesting of Restricted Stock Units granted by the issuer.

F4: Gives effect to a 1-for-4 reverse stock split effected by the Issuer on June 5, 2014.